These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23519576)

  • 1. Dabigatran does not prolong the QT interval with supratherapeutic exposure: a thorough QT study in healthy subjects.
    Ring A; Rathgen K; Stangier J; Reilly P; Clemens A; Friedman J
    Clin Drug Investig; 2013 May; 33(5):333-42. PubMed ID: 23519576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
    de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
    Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study.
    Morganroth J; Gretler DD; Hollenbach SJ; Lambing JL; Sinha U
    Expert Opin Pharmacother; 2013 Jan; 14(1):5-13. PubMed ID: 23216423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
    Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
    Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.
    Kempsford R; Allen A; Kelly K; Saggu P; Crim C
    Br J Clin Pharmacol; 2014 Mar; 77(3):466-79. PubMed ID: 24093504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
    German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study.
    Ring A; Brand T; Macha S; Breithaupt-Groegler K; Simons G; Walter B; Woerle HJ; Broedl UC
    Cardiovasc Diabetol; 2013 Apr; 12():70. PubMed ID: 23617452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers.
    Härtter S; Sennewald R; Schepers C; Baumann S; Fritsch H; Friedman J
    Eur J Clin Pharmacol; 2013 Mar; 69(3):327-39. PubMed ID: 22782539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
    Clemens A; van Ryn J; Sennewald R; Yamamura N; Stangier J; Feuring M; Härtter S
    Eur J Clin Pharmacol; 2012 May; 68(5):607-16. PubMed ID: 22252796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
    Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
    Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo- and active-controlled assessment of 6- and 50-mg oral doxepin on cardiac repolarization in healthy volunteers: a thorough QT evaluation.
    Mansbach RS; Ludington E; Rogowski R; Kittrelle JP; Jochelson P
    Clin Ther; 2011 Jul; 33(7):851-62. PubMed ID: 21722958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
    Ring A; Port A; Graefe-Mody EU; Revollo I; Iovino M; Dugi KA
    Br J Clin Pharmacol; 2011 Jul; 72(1):39-50. PubMed ID: 21306414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.
    Eriksson BI; Dahl OE; Ahnfelt L; Kälebo P; Stangier J; Nehmiz G; Hermansson K; Kohlbrenner V
    J Thromb Haemost; 2004 Sep; 2(9):1573-80. PubMed ID: 15333033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
    Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
    Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers.
    Kropeit D; Johnson M; Cawello W; Rudd GD; Horstmann R
    Acta Neurol Scand; 2015 Nov; 132(5):346-54. PubMed ID: 25932544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.